MNPR

Monopar Therapeutics Inc

Add to Watchlist

Advanced Chart

80.420

-6.59(-7.574%)1D

Line

Candle

YTD

High

83.340

Open

81.225

VWAP

81.19

Vol

145.38K

Mkt Cap

575.28M

Low

76.540

Amount

11.80M

EV/EBITDA(TTM)

Total Shares

17.48M

437.78M

EV/OCF(TTM)

P/S(TTM)

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.742

+95.23%

-0.492

-82.13%

-0.399

-78.44%

Estimates Revision

The market is revising No Change the revenue expectations for Monopar Therapeutics Inc. (MNPR) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 124.26%.

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+124.26%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast MNPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNPR is 109.91 USD with a low forecast of 85.00 USD and a high forecast of 142.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

Current: 80.420

Low

85.00

Averages

109.91

High

142.00

Current: 80.420

Low

85.00

Averages

109.91

High

142.00

Raymond James

Christopher Raymond

Strong Buy -> Outperform

downgrade

$142 -> $123

2025-11-14

New

Reason

Raymond James

Christopher Raymond

Price Target

$142 -> $123

2025-11-14

New

downgrade

Strong Buy -> Outperform

Reason

Raymond James analyst Christopher Raymond downgraded Monopar Therapeutics to Outperform from Strong Buy with a price target of $123, down from $142. The firm cites a higher risk profile than anticipated for the downgrade. The firm's key opinion leader feedback indicates a "heavier commercial" lift than first imagined for Monopar in Wilson disease. A " higher risk premium to our estimates is warranted here," the analyst tells investors in a research note.

Leerink

Outperform

initiated

$115

2025-11-10

New

Reason

Leerink

Price Target

$115

2025-11-10

New

initiated

Outperform

Reason

Leerink initiated coverage of Monopar Therapeutics with an Outperform rating and $115 price target. The firm notes lead asset ALXN1840 produced positive data in the Phase 3 FoCus study, which combined with long-term data and anecdotal reports of substantial patient benefit noted by physicians and the company, provides Leerink with relative optimism that the totality of the data supports a regulatory submission with the FDA and an eventual approval. The firm assumes gross peak sales of about $1.3B for ALXN1840 in Wilson disease. Based on the positive data generated and stage of development, Leerink ascribes a 65% probability of success. Further, the firm thinks shares can move higher over the next 12+ months with regulatory progress and a commercial launch on the horizon.

H.C. Wainwright

upgrade

$70 -> $105

2025-09-29

Reason

H.C. Wainwright

Price Target

$70 -> $105

2025-09-29

upgrade

Reason

H.C. Wainwright raised the firm's price target on Monopar Therapeutics to $105 from $70 and keeps a Buy rating on the shares. A recently published peer-reviewed Letter to the Editor in the Journal of Hepatology presented a re-analysis of the Phase II ALXN1840-WD-204 trial, which evaluated copper balance in Wilson disease patients treated with ALXN1840. The letter challenges the sponsor's earlier findings, arguing they were based on a flawed methodology that considered only urinary and fecal excretion, according to a research note to investors. The re-analysis showed that ALXN1840 actually improved copper balance over the course of the study, the firm reports.

Piper Sandler

Biren Amin

Overweight

maintain

$76 -> $95

2025-09-25

Reason

Piper Sandler

Biren Amin

Price Target

$76 -> $95

2025-09-25

maintain

Overweight

Reason

Piper Sandler analyst Biren Amin raised the firm's price target on Monopar Therapeutics to $95 from $76 and keeps an Overweight rating on the shares. The firm notes the company highlighted a new analysis of the Phase 2 ALXN1840-WD-204 study that disputes the earlier conclusion regarding ALXN1840's lack of effect on copper excretion in patients with Wilson Disease. By considering all pathways of copper loss, beyond just fecal and urinary excretion, this analysis demonstrates that ALXN1840 effectively promotes copper excretion. Herein, Piper also compares and contrasts the recent accelerated approval of Stealth Bio's elamipretide in Barth syndrome, as it sees several parallels that bode well for ALXN1840's potential approval with NDA filing expected in Q1 2026.

Chardan

Keay Nakae

Buy

upgrade

$60 -> $85

2025-09-25

Reason

Chardan

Keay Nakae

Price Target

$60 -> $85

2025-09-25

upgrade

Buy

Reason

Chardan analyst Keay Nakae raised the firm's price target on Monopar Therapeutics to $85 from $60 and keeps a Buy rating on the shares. In a letter to the editor published in The Journal of Hepatology, a new analysis of data showed that ALXN1840 rapidly improves copper balance in Wilson disease patients, the analyst tells investors in a research note.

Cantor Fitzgerald

NULL

Overweight

upgrade

$74 -> $109

2025-09-24

Reason

Cantor Fitzgerald

Price Target

$74 -> $109

2025-09-24

upgrade

NULL

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Monopar Therapeutics to $109 from $74 and keeps an Overweight rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Monopar Therapeutics Inc (MNPR.O) is -37.46, compared to its 5-year average forward P/E of -6.05. For a more detailed relative valuation and DCF analysis to assess Monopar Therapeutics Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.05

Current PE

-37.46

Overvalued PE

1.04

Undervalued PE

-13.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.93

Current PS

87.01

Overvalued PS

9.69

Undervalued PS

-7.82